Does continuous glucose monitoring reduce post-operative delirium in critically ill adults? A systematic review and meta-analysis
Published
May 7, 2025
Paper ID
PAP-000043
Status
Published
DOI
10.65712/tmj.test000301
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on continuous glucose monitoring. Methods: The primary outcome was post-operative delirium, assessed blind to allocation. Results: post-operative delirium occurred in 5% of the intervention group versus 13% of controls. Serious adverse events were rare and similar between groups. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
Practice around continuous glucose monitoring varies widely between centres. Earlier studies of continuous glucose monitoring were small or single-centre. post-operative delirium remains a leading cause of avoidable harm among critically ill adults. Guidelines make only a weak recommendation on continuous glucose monitoring.
Guidelines make only a weak recommendation on continuous glucose monitoring. Practice around continuous glucose monitoring varies widely between centres.
Discussion
Residual confounding cannot be excluded. Future work should test continuous glucose monitoring in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
These findings suggest that continuous glucose monitoring is associated with better post-operative delirium in critically ill adults. Implementation will depend on staffing, cost and local protocols.
These findings suggest that continuous glucose monitoring is associated with better post-operative delirium in critically ill adults. Residual confounding cannot be excluded. Future work should test continuous glucose monitoring in a pragmatic multicentre trial.
Conclusions
Continuous glucose monitoring is a reasonable option for critically ill adults to improve post-operative delirium.
References
1. Novak C, Osei L, et al. Tranexamic acid and in-hospital mortality. Lancet. 2014;49(9):460-1755.
2. Dubois W, Haddad T, et al. Early mobilisation and time to diagnosis. BMJ. 2023;143(1):435-1633.
3. Osei F, Costa Z, et al. Home-based cardiac rehabilitation and glycaemic control. BMC Med. 2020;305(12):411-1645.
4. Okafor Q, Haddad R, et al. Low-dose aspirin and medication adherence. JAMA. 2022;176(12):579-1305.
5. Ahmed U, Farouk F, et al. Point-of-care ultrasound and 30-day readmission. JAMA. 2022;396(7):411-1478.
Appendices
Supplementary tables are available on request.
Materials and Methods
Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.
Eligible participants were critically ill adults. We conducted a systematic review and meta-analysis across 8 centres between 2014 and 2021. We conducted a systematic review and meta-analysis across 7 centres between 2015 and 2023.
Eligible participants were critically ill adults. Analyses were adjusted for age, sex and baseline severity.
Results
post-operative delirium occurred in 22% of the intervention group versus 34% of controls. post-operative delirium occurred in 7% of the intervention group versus 37% of controls. post-operative delirium occurred in 18% of the intervention group versus 19% of controls.
Effects were consistent across prespecified subgroups. post-operative delirium occurred in 4% of the intervention group versus 21% of controls. post-operative delirium occurred in 6% of the intervention group versus 22% of controls.
Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.67 (95% CI 0.21 to 0.78). Effects were consistent across prespecified subgroups.
| Group | n | Events |
|---|---|---|
| Intervention | 792 | 82 |
| Control | 441 | 69 |
| Age < 65 | 297 | 47 |
| Centre A | 356 | 75 |
| Control | 692 | 46 |
Values are n (%) unless stated otherwise.

Shown for critically ill adults; error bars are 95% confidence intervals.
post-operative delirium occurred in 10% of the intervention group versus 33% of controls. The adjusted odds ratio was 0.63 (95% CI 0.24 to 0.88). Serious adverse events were rare and similar between groups.